

OKLAHOMA HEALTH CARE AUTHORITY
REGULAR BOARD MEETING
March 25, 2026, at 2:00 P.M.
Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, OK. 73105

AGENDA

Public access via Zoom:

https://www.zoomgov.com/webinar/register/WN_h3wPpgn1S3Cat1L-l_GrWg

Telephone: 1-669-216-1590 Webinar ID: 160 201 4392

*Please note: Since the physical address for the OHCA Board Meeting has resumed, any livestreaming option provided is provided as a courtesy. Should such livestreaming option fail or have technical issues, the OHCA Board Meeting will not be suspended or reconvened because of this failure or technical issue.

1. Call to Order / Determination of Quorum.....Marc Nuttle, Chair
2. Discussion and Vote on the November 10, 2025, OHCA Board Meeting Minutes.....Marc Nuttle, Chair
3. Chief Executive Officer Report.....Clay Bullard, Chief Executive Officer
 - a) Member Moment
4. State Medicaid Director Update.....Melissa Miller, State Medicaid Director
5. Discussion of Report from the Pharmacy.....Jeffrey Cruzan, MD
Advisory Committee and Possible Action Regarding Chair, Pharmacy Advisory Committee
Drug Utilization Review Board Recommendation:
 - a) Discussion and Possible Vote on Recommendations Made by the Drug Utilization Review Board Pursuant to 63 O.S. § 5030.1, § 5030.3 To Add the Following Drugs to the Utilization and Scope Prior Authorization Program under OAC 317:30-5-77.2(e) (Attachment “A”):

Item:	Drug Name:	Used For:
i.	Keytruda Qlex™ (Pembrolizumab/Berahyaluronidase Alfa-pmph) Opdivo Qvantig™ (Nivolumab/Hyaluronidase nyhy)	Multiple Cancer Diagnoses
ii.	Imaavy™ (Nipocalimab-aahu)	Myasthenia Gravis (MG)
iii.	Wayrilz™ (Rilzabrutinib)	Chronic Immune Thrombocytopenia (ITP)
iv.	Zepbound® (Tirzepatide)	Obstructive Sleep Apnea (OSA)
v.	Redemplo® (Plozasiran)	Familial Chylomicronemia Syndrome (FCS)
vi.	Polyethylene Glycol 3350 (PEG 3350/Sodium Sulfate/Sodium Chloride/Potassium Chloride/Sodium Ascorbate/Ascorbic Acid for Oral Solution (generic MoviPrep®)	Bowel Preparation before Colonoscopy
vii.	Gomekli® (Mirdametinib) Papzimeos™ (Zopapogene Imadenovec-drba) Romvimza™ (Vimseltinib)	Neurofibromatosis Type 1 (NF1) Recurrent Respiratory Papillomatosis (RRP) Tenosynovial Giant Cell Tumors (TGCT)

6. Discussion of Report from the.....Phillip Kennedy
Compliance Advisory Committee Chair, Compliance Advisory Committee
and Possible Action
- a) Discussion and Possible Vote regarding the Authority's ability to withstand the procurement decision
made by the CEO based on the Authority's budget and available funds pursuant to 63 O.S. Section
5006(A)(2) under OAC 317:10-1-16. (Attachment "B")
- i. Non-Emergency Medical Transportation
ii. Health Management Program
7. Discussion of Report from the.....Kevin Corbett
Managed Care Oversight Committee Chair, Managed Care Oversight Committee
8. Discussion of Report of Strategic.....Marc Nuttle, Chair
Planning & Operational Advisory Committee Chair, Strategic Planning & Operational Advisory Committee
9. Adjournment.....Marc Nuttle, Chair

NEXT BOARD MEETING
May 20, 2026, at 2:00PM
Oklahoma Health Care Authority
4345 N. Lincoln Blvd
Oklahoma City, OK 73105